rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Apyx Medical Corporation

APYX · Nasdaq

Health CareMedical DevicesNot moving yet

APYX stood above a rising 150-day average in 40 of the last 52 weekly readings, and has been out of that trend for the last 10 weeks. It is 29.8% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 10
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
68 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 40 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders68+2 on the quarter
New · exited12 · 10
Reported value$95.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ROYCE & ASSOCIATES LPadded · filed 14 Aug 20263,274,064$14.7M+662,840+25.4%
Nantahala Capital Management, LLCreduced · filed 14 Aug 20263,270,248$14.7M-170,056−4.9%
Archon Capital Management LLCreduced · filed 14 Aug 20262,644,717$11.9M-146,206−5.2%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20261,534,847$6.9M-20,425−1.3%
ESSEX INVESTMENT MANAGEMENT CO LLCadded · filed 6 Aug 20261,136,630$5.1M+235,232+26.1%
AIGH Capital Management LLCadded · filed 7 Aug 20261,128,343$5.1M+23,373+2.1%
Silverberg Bernstein Capital Management LLCreduced · filed 7 Jul 20261,039,641$4.7M-1,429−0.1%
COMMONWEALTH EQUITY SERVICES, LLCunchanged · filed 29 Jul 2026649,061$2.9M00.0%
HORIZON KINETICS ASSET MANAGEMENT LLCreduced · filed 11 Aug 2026585,000$2.6M-30,000−4.9%
BlackRock, Inc.added · filed 7 Aug 2026560,986$2.5M+33,238+6.3%
31 Mar 2023 – 30 Jun 2026
375267Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Lawrence Waldman Company insiderDirector · last 30 Jun 20260 · 0
Shawn David Roman Company insiderChief Operating Officer · last 15 Jun 20260 · 0
Charles D. Goodwin II Company insiderChief Executive Officer · last 11 Jun 20263 · 0
Matthew C. Hill Company insiderChief Financial Officer · last 11 Jun 20263 · 0
Minnie Baylor-Henry Company insiderDirector · last 11 Jun 20260 · 0
Moshe Citronowicz Company insiderSr. V.P. of Operations · last 11 Jun 20261 · 11
Stavros G. Vizirgianakis Company insiderDirector · last 11 Jun 20260 · 0
Wendy Lauren Levine Company insiderDirector · last 11 Jun 20260 · 0
Craig A. Swandal Company insiderDirector · last 8 Aug 20240 · 0
John C. Andres Company insiderDirector · last 8 Aug 20240 · 0
Michael Geraghty Company insiderDirector · last 8 Aug 20240 · 0
Todd Hornsby Company insiderExecutive Vice President · last 10 Jan 20240 · 2

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202562.5%
Operating profit marginFY 2025 · to 31 Dec 2025-12.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-17.2%
Return on capital employedFY 2025 · to 31 Dec 2025-11.7%
Debt to equityFY 2025 · to 31 Dec 20252.58×
Research spendFY 2025 · to 31 Dec 20256.4%
Share count trendFY 2025 · to 9 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$31.7M
Free cash flowFY 2025 · to 31 Dec 2025−$9.1M

Analyst forecasts

No analyst forecasts yet.